Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Argos Therapeutics has reported positive immune response data from a Phase I clinical trial of AGS-004 in HIV-infected adults in combination with antiretroviral therapy.
Subscribe to our email newsletter
AGS-004 achieved the trial’s primary endpoint of induction of T cell response to patient-specific HIV antigens. AGS-004 is a personalized HIV immunotherapy generated by the company’s Arcelis technology.
According to the company, Arcelis is an immunotherapy platform for creating personalized, RNA-loaded dendritic cell-based therapies perfectly matched to each patient’s unique virus.
John Bonfiglio, president and CEO of Argos, said: “We believe that these data support our multi-center Phase IIa trial investigating the efficacy of AGS-004 in improving the immune system’s ability to control viral replication in the absence of antiretroviral therapy.”
Argos also successfully demonstrated manufacturing feasibility and production consistency of AGS-004. AGS-004 is currently undergoing a Phase IIa proof-of-concept trial.